

Announcement from 09.12.2015 / 16.30

Elanix Biotechnologies AG: Restructuring to Biotech Company

Elanix Biotechnologies AG / Key word(s): other

09.12.2015 16.30

Publishing of an ad hoc announcement as per §15 pursuant to German Securities Trading Law (WpHG), transmitted by DGAP – a service of the EQS Group AG.

The issuer is responsible for the content of this announcement.

Elanix Biotechnologies AG (former Porta Systems AG): Restructuring to Biotech Company

Elanix Biotechnologies AG

Today, 9 of December 2015, the Registration Court in Bad Oeynhausen registered the main decisions of Biotech Company's General Meeting on 22.09.2015 in the Commercial Register. From today the Company will be acting as Elanix Biotechnologies AG.

The Company's share capital rose from EUR 516,000 to EUR 5,166,000. This increase by EUR 4,649,400, was due to the issuing of 4,649,400 new bearer shares against tangible assets purchased under exclusion of the purchase right. The tangible assets are namely all Elanix Technologies AG's shares, a BioTech Company based in Nyon, Switzerland.

The name of the Company was changed to "Elanix Biotechnologies AG", whose corporate purpose is as follows: "The corporate purpose of the Company is the manufacturing and distribution of products, as well as any other commercial activities and services in the areas of health care, medicine, cosmetics and Bio Technologies."

A copy of the Commercial Register entry can be found here:

<http://www.porta-ag.de/resources/HREintragSacheinlage.pdf>

9.12.2015 – The DGAP distribution services include Regulatory Announcements, Corporate News / Finances and press releases. DGAP media archive at www.dgap-medientreff.de and www.dgap.de

Language: German
Company: Elanix Biotechnologies AG
Fritz-Vomfelde-Str
40547 Düsseldorf
Germany
Phone:
Fax:
E-mail:
Internet:
ISIN: DE000A0WMJQ4, DE000A0L1MM9
WKN: A0WMJQ
Stock exchange: Regulated Market in Frankfurt (General Standard);
Open Market in Berlin, Düsseldorf

End of announcement

DGAP News Service
